presentation to T cells (Hartgers et al. 2000) . The engagement of DC-STAMP in osteoclastogenesis during cell fusion was first demonstrated in an in vitro study in 2004 (Kukita et al. 2004 ). Furthermore, DC-STAMP-deficient mice showed an increase in bone mass, while DC-STAMP-Tg mice showed decreased bone mass in comparison to their wild-type mice . These results suggest that DC-STAMP plays a role in OC cell fusion, thereby promoting the bone catabolic effects elicited by OCs in the physiological context (Yagi et al. 2006; Xing et al. 2012; Zhang et al. 2014) . The level of DC-STAMP messenger RNA (mRNA) expression is also elevated in patients with periodontitis (Belibasakis et al. 2011) . Nevertheless, the role of DC-STAMP in the course of the bone lytic lesion development in periodontal disease is largely unknown.
We and others demonstrated that an adaptive immune response to oral bacteria is associated with periodontal bone loss (Valverde et al. 2004; Han et al. 2006 ). This finding is based on the observation that activated lymphocytes produce both host protective antibody and cytokines, and they express RANKL, the key osteoclastogenesis factor (Kawai et al. , 2007 . Importantly, in a mouse model of periodontitis, the mouse oral commensal bacterium Pasteurella pneumotropica (Pp, phylogenetically closely related to Aggregatibacter actinomycetemcomitans) was found to be immunodominant (Kawai et al. 2007 ). Because antigen presentation required for adaptive immune activation occurs in remote lymph nodes, it was hypothesized that local DC-STAMP-specific blockade in the affected periodontal tissue could inhibit osteoclastic activity and do so without affecting host-protective antibacterial antibody response, finally resulting in the inhibition of alveolar bone resorption that occurs in periodontitis. To test this hypothesis, an anti-DC-STAMP-monoclonal antibody (mAb) was developed to inhibit DC-STAMP-mediated OC fusion. Therefore, using a mouse model of ligature-induced periodontitis, this study aimed to 1) examine the expression profile of DC-STAMP in the course of periodontitis development and 2) test the effect of local DC-STAMP-mAb administration on alveolar bone resorption, while assessing antibacterial immune responses by the activity to present antigen to T cells.
Materials and Methods
Animals C57BL/6J mice were bred in the Forsyth animal facility. Experimental procedures using mice were approved by the Forsyth Institutional Animal Care and Use Committee (IACUC). This study was performed in accordance with ARRIVE (Animal Research: Reporting of In Vivo Experiments) guidelines for preclinical animal studies.
Design of Anti-DC-STAMP Neutralizing mAb
A mAb to mouse DC-STAMP was developed as described elsewhere (Kawai et al. 1998; Movila et al. 2016) . Procedures are explained in the Appendix.
Western Blot
Western blot was used to determine the specificity of mAb following the method published previously (Kawai et al. 1998 ).
Mouse Bone Marrow Cell Culture and OC Differentiation Assay
Bone marrow mononuclear cells (BMMCs) isolated from femur and tibia of mice were seeded into 96-well plates (10 5 cells/well) in α-MEM with 10% fetal bovine serum and 30 ng/ mL macrophage colony-stimulating factor (M-CSF; R&D Systems). After preincubation with M-CSF (30 ng/mL) for 2 d, murine soluble RANKL (sRANKL; 50 ng/mL; BioLegend) was added to the culture with or without anti-DC-STAMP-mAb (mouse IgG2a) or control irrelevant mouse mAb (anti-Porphyromonas gingivalis-mAb, mouse IgG2a). OCs in the culture were identified using the acid phosphatase leukocyte (tartrateresistant acid phosphatase [TRAP]) kit (Sigma-Aldrich) at day 7 after RANKL stimulation. TRAP-positive cells, containing 3 nuclei or more, were counted microscopically. The boneresorptive activity of OCs was evaluated by a pit formation assay using the Osteo Assay Surface plate (Corning).
RNA Extraction and Real-Time Polymerase Chain Reaction
Total RNA was extracted from the cultured mouse BMMCs after RANKL stimulation and gingival tissues, following the previously published method (Valverde et al. 2004 ). Gene expression was quantified using LightCycler 480 SYBR Green I Master (Roche Diagnostics). The primer sequences used were DC-STAMP, F: TCCTCCATGAACAAACAGTTCCAA, R: AGACGTGGTTTAGGAATGCAGCTC (Miyamoto et al. 2012 ) and TRAP, F: CCAGCGACAAGAGGTTCC, R: AGAGACGTTGCCAAGGTGAT. Amplification of the betaactin gene was used as an internal control.
Local and Systemic Application of Anti-DC-STAMP-mAb in a Ligature-Induced Periodontitis Mouse Model
Silk ligatures (5-0; Ethicon) were placed on the upper left second molars of C57BL/6J mice (male 6-7 wk old), whereas the upper right second molar without ligature was used as a control. Local gingival injection of anti-DC-STAMP-mAb or control-mAb (10 µg/site, n = 6-7/group), respectively, was performed at the ligature-placed and control sites at the time of ligature placement. To evaluate the effects of systemic administration of mAbs, intraperitoneal injection of anti-DC-STAMP-mAb or control-mAb (5 mg/mice, respectively) was performed immediately after ligature attachment (n = 5/group). Gingival tissues were collected from sacrificed mice (days 3, 7, and 14) for the detections of proinflammatory cytokines by enzyme-linked immunosorbent assay (ELISA). Total alveolar bone loss was calculated by summing cemento-enamel junction (CEJ) to the alveolar crest (AC) distances of distal root of first molar, mesial, mid-buccal, and distal root of the second molar and mesial root of the third molar (Kawai et al. 2007 ) using a dissection microscope (Nikon) and micro-computed tomography (micro-CT) scanning (Scano Medical AG). The 3-dimensional bone volume quantification was analyzed using Amira software (FEI Visualization Sciences Group). Gingival tissue homogenates for ELISA were prepared as previously described (Kawai et al. 2007) . Tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, and RANKL levels were determined using commercially available ELISA kits (DuoSet ELISA; R&D Systems). All postmortem examinations were performed in a blinded manner.
Histological Staining of Periodontal Tissue Sections
Mice maxillae fixed in 10% formaldehyde were decalcified in 10% EDTA solution. Decalcified samples were embedded in paraffin and sectioned (7-µm thickness). TRAP staining was performed as previously described (Lin et al. 2011) . For immunofluorescence staining, the specimens were embedded in OCT compound (Sakura Finetek) and sectioned (7-µm thickness) using a cryostat. The expression of DC-STAMP was monitored using biotin-conjugated anti-DC-STAMP-mAb, followed by avidin-conjugated to AlexaFluor 488. RANKLexpressing T cells infiltrating in the periodontal tissue were stained with OPG-Fc-Biotin/avidin-AlexaFluor 488 and AlexaFluor 647.
T-Cell Proliferation Assays and Immunoglobulin G Response to Oral Bacteria
T cells were isolated from cervical lymph node of mice that received ligature attachment for 14 d. The enriched T cells using glass/nylon-wool column (Kawai et al. 1999) were cultured in 96-well plates (2.5 × 10 5 cells/well) in the presence or absence of mouse DCs (5 × 10 4 cells/well) with or without fixed Pp or fixed Staphylococcus xylosus (Sx) (10 7 /well) as antigen. DCs were generated by incubation of BMMCs isolated from femur and tibia of C57BL/6J mice with granulocyte macrophage colony-stimulating factor (GM-CSF) (20 ng/mL) for 6 d, followed by additional 1-to 2-d culture with lipopolysaccharide (1 µg/mL, Escherichia coli; Sigma). Either anti-DC-STAMP-mAb or control-mAb (50 µg/mL) was added to the T-cell cultures. The proliferation of T cells was assessed using the thymidine incorporation assay (Kajiya et al. 2009 ). The culture supernatant was collected to monitor sRANKL by ELISA. To detect antibacterial immunoglobulin G (IgG) levels in serum, the formalin-fixed bacteria/bacterial sonicate of Pp and Sx was used as antigen in the ELISA assay (Kawai et al. 2007 ).
Statistical Analysis
Student's t test was used to compare 2 different outcomes of experiments performed. Nonparametric data were evaluated using the Mann-Whitney U test or 1-way analysis of variance (ANOVA) for 2-group comparisons. A P value <0.05 was considered statistically significant.
Results

DC-STAMP was detected on RANKL-induced OCs in vitro and was localized in periodontitis lesions in vivo.
In response to M-CSF/RANKL stimulation, quantitative real-time polymerase chain reaction (qRT-PCR) showed upregulation of DC-STAMP mRNA in BMMCs, peaking at 24 h, followed by a gradual reduction (Fig. 1A) . The specificity and functionality of developed anti-DC-STAMP-mAb were confirmed in the Western blot and osteoclastogenesis assay in which immune-peptide (DCST-L3pep) blocked the activities of anti-DC-STAMP-mAb, supporting the epitope specificity and functionality of this mAb (Fig. 1B) . Immunofluorescence staining of BMMCs stimulated with M-CSF/RANKL for 5 d showed DC-STAMP expressed on the peripheral membrane of both small mononuclear OCs and large multinuclear OCs (Fig.  1C ). Next, expression of DC-STAMP-mRNA in periodontal lesion in vivo was evaluated. qRT-PCR from gingival tissue showed increased DC-STAMP-mRNA expression at days 3, 7, and 14, whereas TRAP-mRNA expression was increased at days 7 and 14 ( Fig. 1D ). Immunofluorescence staining of DC-STAMP was also performed in frozen sections of maxilla from ligatured periodontitis mice sacrificed at day 7. Elevated number of cells that express DC-STAMP on their cell surface was observed in the periodontitis lesion compared with the healthy periodontium of control mice (Fig. 1E ).
Anti-DC-STAMP-mAb Showed the Engagement of DC-STAMP in OC Fusion In Vitro
TRAP staining results showed that anti-DC-STAMP-mAb significantly inhibited OC cell fusion in vitro. The number of TRAPpositive multinucleated OCs was significantly lower in the anti-DC-STAMP-mAb-treated group compared with the group without treatment or control. In addition, the decrease in the number of OCs was more pronounced in larger cells containing <10 nuclei than smaller cells with 3 to 10 nuclei ( Fig. 2A, C) , suggesting that DC-STAMP is engaged in promotion of cell fusion. In the pit formation assay, the resorbed area was significantly reduced in OCs cultured with anti-DC-STAMP-mAb ( Fig. 2B, D ).
RANKL Production from T Cells Contributes to Periodontal Bone Resorption in Ligatured Model
IgG antibody against Pp, a keystone commensal bacterium in mouse oral cavity, was significantly elevated by ligature attachment, whereas another oral bacterium, Sx, did not induce IgG after ligature attachment (Fig. 3A) . Importantly, cervical lymph node T cells isolated from mice that received ligature attachment showed elevated antigen-specific proliferation in vitro, along with increased production of RANKL, in response to Pp antigen but not Sx antigen (Fig. 3B ). Therefore, in the ligature-induced periodontitis model, these results suggest that adaptive immune response to Pp triggers RANKL-mediated periodontal bone loss.
To assess the role of adaptive immune response in ligatureassociated bone loss, we assessed RANKL expression in frozen sections of periodontal tissue. In tissues from mice with ligature, RANKL expression was found on both CD3-positive and CD3-negative cells (Fig. 3C ). Corresponding to our previous report showing that most RANKL+ inflammatory infiltrates were T cells in mouse periodontitis, of which periodontal bone loss was associated with anti-Pp immune response (Kawai et al. 2007 ), most RANKL+ cells were CD3-positive cells (Fig. 3C ). These findings indicate that the periodontal bone loss induced by ligature is associated with the production of RANKL induced by Pp-reactive adaptive immune response.
Anti-DC-STAMP-mAb Reduced Periodontal Bone Resorption in Periodontal Disease
Next, we asked if DC-STAMP regulated bone resorption in response to ligature attachment. Significantly, elevated bone loss was detected at day 7, and it increased at day 14 after ligature attachment. Importantly, on both days 7 and 14, local injection of anti-DC-STAMP-mAb significantly suppressed ligature-triggered bone resorption compared with the group that received control-mAb ( Fig. 4A-D) . It is noteworthy that systemic administration of anti-DC-STAMP mAb also significantly reduced the bone resorption compared with the group that received control-mAb at day 14 (Fig. 4E) . The effect of anti-DC-STAMP-mAb on osteoclastogenesis in vivo was also assessed by TRAP staining in the tissue sections sampled on day 7. Anti-DC-STAMP-mAb dramatically suppressed the emergence of TRAP-positive multinucleated cells in the alveolar bone surface compared with those found in the group that received control-mAb ( Fig. 4F, G) . These results strongly suggest that locally administered anti-DC-STAMP-mAb reduced alveolar bone resorption through the inhibition of osteoclastogenesis.
Attachment of ligature also induced the production of proinflammatory cytokines (i.e., TNF-α and IL-1β) in the gingival tissue throughout all measurement points (days 3, 7, and 14) (P < 0.05). However, elevated cytokines in the ligatured gingiva were comparable between the groups that received anti-DC-STAMP-mAb and control-mAb. Significantly, elevated production of RANKL was detected at day 3 but not day 7 or 14. However, such elevated RANKL detected at day 3 was unaffected by the local injection of anti-DC-STAMP-mAb (Fig.  5A) . Thus, abrogation of DC-STAMP reduces bone loss following ligature attachment without altering the inflammatory milieu or the level of RANKL. 
Adaptive Immunity Was Unaffected by Localized Application of Anti-DC-STAMP-mAb
Since DC-STAMP is expressed on DCs in addition to OC precursors, we investigated the effects of anti-DC-STAMP-mAb on bacterial (Pp) antigen presentation by DCs to T cells that were isolated from ligatured mice. In the co-culture between DCs and T cells, anti-major histocompatibility complex (MHC) II-mAb significantly suppressed Pp-reactive T-cell proliferation, as well as sRANKL production, from T cells exposed to Pp presented by DCs, suggesting that DCs present Pp to T cells in an MHC IIdependent manner. However, anti-DC-STAMP-mAb altered neither T-cell proliferation in response to Pp antigen nor sRANKL production from T cells activated by Pp antigen (Fig. 5B) , suggesting that anti-DC-STAMP-mAb does not affect DC-mediated antigen presentation to T cells. In addition, elevated IgG antibody response to Pp induced by ligature attachment was not altered by local administration of anti-DC-STAMP-mAb (Fig. 5C ). In sum, these results from T-cell and antibody (B-cell) responses suggest that topical application of anti-DC-STAMP-mAb suppresses RANKLinduced periodontal bone loss without affecting adaptive immune responses.
Discussion
In this study, we demonstrated that the expression of DC-STAMP mRNA and protein is upregulated in periodontitis lesions induced in mice. Furthermore, locally administered anti-DC-STAMP-mAb could inhibit periodontal bone resorption via suppression of OC fusion without affecting T-and B-cell response to oral bacteria. Fusion of preosteoclasts plays a vital role in the maturation of OCs as only multinucleated OCs can elicit bone-resorbing activity (Yagi et al. 2006; Xing et al. 2012; Zhang et al. 2014 ). Studies point out various candidate molecules that act as mediators of OC fusion (Miyamoto 2011; Xing et al. 2012; Willkomm and Bloch 2015) , including CD9 (Ishii et al. 2006) , DC-STAMP (Yagi et al. 2005) , Atp6v0d2 (Kim et al. 2008) , and OC stimulatory transmembrane protein (OC-STAMP) (Yang et al. 2008 ). However, among them, DC-STAMP appears to play a pivotal role in OC fusion based on the severe osteopetrotic phenotype of DC-STAMP-knockout (KO) mice and the inability of OC precursors isolated from DC-STAMP-KO mice to generate multinuclear TRAP+ cells in vitro (Miyamoto 2011; Zhang et al. 2014) . The present study demonstrated that local gingival injection of anti-DC-STAMP-mAb downmodulated OC fusion in vitro and neither affected the production of proinflammatory cytokines, including RANKL, nor altered T-and B-cell responses. Therefore, it is very likely that anti-DC-STAMP-mAb suppresses OC fusion in the context of periodontitis without modulating T-and B-cell responses. Since antibodies play a major role in antibacterial adaptive immune response, the fact that anti-DC-STAMP-mAb had no effect on IgG antibody response to oral bacteria, while suppressing osteoclastogenesismediated bone loss, can be an advantage in developing a therapeutic regimen for periodontitis. A, B) Images of tartrate-resistant acid phosphatase (TRAP) staining and resorption pits are shown for bone marrow mononuclear cell (BMMC)-derived osteoclasts (OCs) at 7 d after stimulation with macrophage colony-stimulating factor (M-CSF) (30 ng/mL) alone or M-CSF (30 ng/mL) and soluble receptor activator of nuclear factor kappa-B ligand (sRANKL) (50 ng/mL) in the presence of anti-DC-STAMP-mAb (50 µg/ mL) or control-mAb (50 µg/mL). Anti-DC-STAMP-mAb significantly reduced OC cell-cell fusion and its resorptive activity in vitro (magnification 40×). (C) The number of TRAP-positive multinucleated OCs was significantly lower in the group that received anti-DC-STAMP-mAb compared with the group without treatment or the group that received control-mAb. In addition, a decrease in the number of OCs was more pronounced in large OCs containing >10 nuclei than small OCs (3-10 nuclei/cell), suggesting that anti-DC-STAMP-mAb inhibits cell fusion during RANKL-induced OC formation (mean ± SD, n = 8; TRAP-positive multinuclear cells, containing 3 or more nuclei, were considered OCs; *P < 0.05 compared with negative control). (D) The images of resorbed area on calcium phosphate-coated plate (B) were quantified and shown in the histogram. The resorbed area was significantly reduced in OCs cultured with anti-DC-STAMP-mAb (mean ± SD, n = 8, *P < 0.05 compared with control). ND, no difference.
Bisphosphonate, a potent drug used for bone lytic diseases, has now been shown to cause bisphosphonate-induced osteonecrosis of the jaw (Ruggiero et al. 2014; Mawardi and Woo 2015) . As a result, the search for alternative regimens for bone lytic diseases, including periodontitis and cancer bone metastasis, has recently accelerated. Such alternative regimens must account for the fact that cell fusion in OCs occurs continuously throughout life, unlike other multinucleated cells, such as trophoblasts and myoblasts, which only undergo fusion during developmental growth (Chen et al. 2007 ). Therefore, a strategy that targets OC multinucleation could lead to the development of novel therapies to treat OC-specific bone loss with minimal side effects. Importantly, it was demonstrated in this article that, unlike to CD9 that is also engaged sperm-egg fusion (Jankovičová et al. 2015) , mAb-mediated local neutralization of DC-STAMP, which is essential for cell fusion in OCs, showed suppression of periodontal bone resorption. Thus, the present study indicates that anti-DC-STAMP-mAb may lead to the development of novel therapeutic regimens for periodontitis and other bone lytic diseases with minimal side effects.
Besides DC-STAMP's role in OC fusion, several studies reported its effects on immune and inflammatory responses. Sawatani et al. (2008) reported that aged DC-STAMP-KO mice show symptoms of autoimmune disease, indicating that DC-STAMP may be associated with downmodulation of agedependent loss of self-tolerance, which, in turn, promotes the T-cell responses to autoantigens. In contrast, anti-DC-STAMP-mAb did not alter T-cell response to Pp antigen presentation by DCs. Eleveld-Trancikova et al. (2005) reported that DC-STAMP is expressed in the endoplasmic reticulum as analyzed by enzyme-linked immunosorbent assay (ELISA), was significantly higher in the mice that received ligature compared with the control mice without ligature. No significant difference was found for IgG antibody response against Staphylococcus xylosus (Sx) antigen (mean ± SD, n = 6 mice/group; *P < 0.05, **P < 0.01). (B) The level of soluble receptor activator of nuclear factor kappa-B ligand (sRANKL) in the gingival tissue was significantly elevated in the site that received ligature compared with the healthy no-ligature site (day 14, ELISA results from gingival homogenates). (C) Infiltration of RANKL+ T cells was observed in the gingival tissue that received ligature placement (day 14, confocal microscope; blue, nucleus; red: CD3; green, RANKL). The number of infiltrated RANKL+ T cells was significantly higher in the gingival tissue of the ligatured group compared with control as presented in the histogram (mean ± SD, n = 4; *P < 0.05). ND, no difference. This figure is available in color online.
(ER) of DCs and that such a DC-STAMP in the ER interacts with a transcription factor (Eleveld-Trancikova et al. 2010) . Since a mAb can only act on the target molecule expressed on the cell surface, but not that in the ER of DCs, it is plausible that anti-DC-STAMP-mAb showed an impact on osteoclastogenesis by neutralizing DC-STAMP expressed on the OCs but not affecting DC-STAMP expressed in the ER of DCs.
The involvement of DC-STAMP in periodontal disease was first examined by Belibasakis et al. (2011) . In this crosssectional clinical study, the expression level of DC-STAMP was elevated in gingival tissues from patients with periodontitis compared with healthy subjects (Belibasakis et al. 2011 ), suggesting that DC-STAMP-mediated OC cell fusion might occur in the local alveolar bone in the context of periodontitis. Apart from this report, which determined the DC-STAMP gene expression profile in human patients with periodontitis, no other study has ever addressed DC-STAMP as an osteoclastic fusogen in periodontitis. It should be noted that anti-DC-STAMP-mAb did significantly suppress periodontal bone loss in conjunction with the reduced number of TRAP+ OCs in the affected tissue compared with control-mAb, suggesting the DC-STAMP play a role in osteoclastogenesis in periodontitis.
In contrast to chemical compound drugs, mAb drugs are attracting interest in the field of clinical translational research based on the expected advantages of added specificity and fewer side effects (Hansel et al. 2010) . Indeed, mAbs, or IgG-based molecules, have advantages over small-molecule drugs in many respects, including high target specificity, long serum half-life and effector functions via complementdependent cytotoxicity, and the capacity for incorporation of functional moieties through conjugation (e.g., mAb-based immunotoxins) (Leavy 2010; Liu 2014 ). An antihuman DC-STAMP-mAb has recently been developed (Chiu et al. 2012 ). It shows antiosteoclastogenesis function similar to that of the antimouse DC-STAMP-mAb used in this study, suggesting anti-DC-STAMP-mAb can (A) Images of ligature-induced bone resorption at maxillary buccal sites of mice that received local injection of mAb are shown (day 7, right, micro-computed tomography; left, dissection microscope). The distances of cemento-enamel junction (CEJ) to alveolar bone crest (ABC) on the roots of molars were measured. (B) Images of the same maxillary samples were cropped from consecutively sliced digital images as region of interest (ROI) using Amira software. Tooth surface is colored in red, while bone is colored in brown. (C) Total periodontal bone loss was calculated by subtracting the sum of the CEJ-ABC distance of the baseline no-ligature site from that of the ligature site. Data are presented in the histogram. Anti-DC-STAMP-mAb significantly suppressed ligature-triggered alveolar bone resorption compared with control-mAb at days 7 and 14 (1.18 vs. 1.68 mm, P < 0.05 and 1.58 vs. 2.28 mm, P < 0.01, respectively) (mean ± SD, n = 6-7 mice/group; *P < 0.05, **P < 0.01). (D) Volumetric analysis was evaluated by global thresholding procedures (bone tissue = 3,409-10,913). Total bone volume is presented as mean ± SD of voxel units calculated by Amira. Mice that received anti-DC-STAMP-mAb showed significantly higher bone volume compared with control group at days 7 and 14 (1.49 vs. 1.12, P < 0.01 and 1.30 vs. 0.91, P < 0.01, respectively) (mean ± SD, n = 3/group, **P < 0.01). (E) Systemic administration of anti-DC-STAMP-mAb (intravenous) significantly reduced ligature-triggered alveolar bone resorption compared with control-mAb at day 14 (0.91 vs. 1.81 mm) (mean ± SD, n = 5 mice/group, *P < 0.05). (F, G) Paraffin sections from decalcified maxilla from the 7-d group were subjected to tartrate-resistant acid phosphatase (TRAP) staining. TRAP-positive multinucleated cells are indicated by the arrowhead (bar = 100 µm). Higher numbers of TRAP+ osteoclast (OCs) (arrow) were found on the alveolar bone surface of the ligature group compared with control (mean ± SD, n = 4, **P < 0.01). Anti-DC-STAMP-mAb decreased the local differentiation of TRAP-positive multinucleated cells. This figure is available in color online.
lead to the development of novel therapeutic approaches to downregulate osteoclastogenesis.
In sum, we, for the first time, discovered that DC-STAMP is a major OC fusogen engaged in osteoclastogenesis during the bone resorption process that occurs in a mouse model of ligatureinduced periodontitis and that a local gingival injection of anti-DC-STAMP-mAb can suppress osteoclastogenesis-mediated periodontal bone loss. Thus, the results in this study may lay the groundwork for the development of a novel therapeutic target against bone loss in periodontal disease, as well as other diseases characterized by systemic bone loss, such as osteoporosis. ) in gingival tissue were measured by enzyme-linked immunosorbent assay (ELISA). No statistical difference was found between groups receiving anti-DC-STAMP-mAb and control-mAb (mean ± SD, n = 4/group; # P < 0.05 compared with the no-ligature group). (B) Bacteria-reactive T-cell response was monitored using 3H-thymidine incorporation assays by the culture of T cells isolated from the cervical lymph node of ligature-induced periodontitis mice. T-cell proliferation was upregulated when challenged with Pasteurella pneumotropica (Pp) antigen. The addition of anti-DC-STAMP-mAb or control-mAb did not alter T-cell proliferation in response to Pp antigen, while anti-major histocompatibility complex (MHC) II-mAb suppressed Pp-reactive T-cell proliferation. The level of sRANKL production in T-cell culture was proportional to T-cell proliferation (mean ± SD, n = 8/group; *P < 0.01 compared with control, # P < 0.05). (C) Serum immunoglobulin G (IgG) antibody response to Pp was analyzed by ELISA. No significant difference in IgG antibody response against Pp antigen was found when compared with control-mAb (mean ± SD, n = 5/group; *P < 0.05). ND, no difference.
